SRT3025 HCl

製品コードS8481 バッチS848101

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C31H31N5O2S2.HCl
分子量 606.2 CAS No. 2070015-26-6
Solubility (25°C)* 体外 DMSO (warmed with 50ºC water bath) 100 mg/mL (164.96 mM)
Ethanol (warmed with 50ºC water bath) 5 mg/mL (8.24 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 SRT3025は、SIRT1酵素の経口投与可能な低分子活性化因子です。
in vitro SRT3025 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway. SRT3025 acts faster than oxymetholone to improve hematopoiesis. It does not work by direct activation of Sirt1 in hematopoietic cells. SRT3025 might suppress p21 transcription through the down-regulation of Egr1. SRT3025 is found to activate wild-type Sirt1 protein but failed to activate the E230K mutant, an activation-resistant Sirt1 protein (due to a mutation at position 230).
in vivo SRT3025 treatment also inhibits tumor growth in Panc-1 xenografts, even though it is not as effective in inhibiting the viability of Panc-1 cells in culture. SRT3025 is well tolerated in mice and has the potential to be used in several diseases. SRT3025 administration expands HSPCs and boosts blood counts while long term SRT3025 administration does not permanently increase or decrease HSC repopulating potential. SRT3025 reduces plasma cholesterol, inflammation, and atherosclerosis in Apoe−/− mice, and it increases hepatic Ldlr expression and Pcsk9 accumulation.

プロトコル(参考用のみ)

細胞アッセイ 細胞株 HPDE, Panc-1, SU86.86, Patu8988t cells
濃度 0-5 μM
反応時間 72 h
実験の流れ

Cells are treated with vehicle or different concentrations of SRT3025 for 72 hours and submitted to MTT analysis. 
動物実験 動物モデル Female athymic nu/nu mice
投薬量 50-200 mg/kg
投与方法 oral administration

参考

  • https://pubmed.ncbi.nlm.nih.gov/26655844/
  • https://pubmed.ncbi.nlm.nih.gov/26226624/
  • https://pubmed.ncbi.nlm.nih.gov/26046330/
  • https://pubmed.ncbi.nlm.nih.gov/24603306/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity [ Cell Rep, 2025, 44(5):115572] PubMed: 40249703
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase [ Lipids Health Dis, 2025, 24(1):14] PubMed: 39825408
Sirtuin activation targets IDH-mutant tumors [ Neuro Oncol, 2021, 23(1):53-62] PubMed: 32710757
Geriatric Fragility Fractures Are Associated With a Human Skeletal Stem Cell Defect [ Aging Cell, 2020, e13164] PubMed: 32537886
Sirt1 in the Regulation of Interferon Gamma in Severe Aplastic Anemia. [ Acta Haematol, 2019, 142(3):142-148] PubMed: 31141802

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。